Provenge, an experimental treatment vaccine for advanced prostate cancer, met researchers’ goal in a key trial needed for FDA approval. That news comes from Dendreon, the company that makes Provenge. "We believe this is truly a breakthrough for the prostate cancer community and a testament to the promise of the field of cancer immunotherapies,"...
Read more »
Cancer
Prostate Cancer Vaccine Meets Goal
Colorectal cancer most common
Taiwan recorded 73,293 new cancer cases in 2006, with the largest number being colorectal cases, according to the latest cancer incidence report released yesterday by the Department of Health=. The figures mean that on average, a new cancer patient was being diagnosed in the country every 7 minutes, 10 seconds in 2006, up slightly...
Read more »
Million Woman Study Links Alcohol Use to Cancer in Women
In seeming contradiction to previous studies where findings supported the benign or beneficial effects of alcohol consumption, a current study by researchers at the University of Oxford in Great Britain has linked even minimal alcohol use and cancer in women. The type of alcohol consumed was irrelevant. The so-called Million Women Study of middle-aged...
Read more »
Testicular cancer linked to marijuana use
Marijuana use could increase the risk of testicular cancer, according to a study by the Fred Hutchinson Cancer Research Center out this week. If a man has smoked marijuana on a weekly basis or has been exposed to hashish for an extended period of time, the chances of testicular cancer double compared to someone...
Read more »
Bone Drugs May Help Fight Breast Cancer
A drug of a class commonly used to combat bone loss may reduce by a third the chance that some breast cancers will spread or recur, a large study has found. While it may sound odd to treat cancer with a drug that acts on bone, evidence is accumulating that such drugs may do...
Read more »
ASA404 to be developed in breast cancer
London, UK, and Cambridge, MA, 12 February 2009 – Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that its Tumour-Vascular Disrupting Agent, ASA404, will be evaluated by Novartis as a treatment for HER2-negative metastatic breast cancer. This indication is being prioritised ahead of prostate cancer, in which a phase II trial has been completed. Details of...
Read more »
Drug Discovery Short-circuits Cancer Growth
A new drug that blocks cancer’s main source of growth has been created in the lab and proven effective in mice, cientists are reporting. It is now being readied for clinical trials in patients. Far more potent than similar compounds already in clinical trial, the drug short-circuits the normal ability of cells to sense...
Read more »